A Strong Start For Amvuttra, But Alnylam Bides Time On Heart Results And US Price Control Plans
Company Will Await Full Readout In 2024
Alnylam has scrapped plans for an interim analysis of its all-important HELIOS-B study of its new ATTR therapy, hoping that a 2024 readout will be more compelling, while the US Inflation Reduction Act has put the brakes on development in another indication.
You may also be interested in...
Alnylam’s Patisiran ATTR-CM Opportunity Boosted By New APOLLO-B Data
Phase III results for Onpattro (patisiran) in ATTR cardiomyopathy pave a path to approval – though the competitive profile is in question – and foreshadow potential success for follow-on drug vutrisiran.
Medicare Drug Pricing Reform Is A Reality: Here Is What’s On The Agenda
Congressional Democrats achieved a long-sought goal in passing major legislation to control drug prices in Medicare. A complete lack of Republican support suggests the programs established by the bill will face the same kind of legislative and legal challenges that confronted the Affordable Care Act, which was enacted in a similar manner.
AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win
AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.